Koay Team Wins Texas Cancer Prevention Funding

Researchers at MD Anderson were selected for Cancer Prevention and Research Institute of Texas funding to study pancreatic cysts linked to cancer.

Updated on Nov. 20, 2026 in Cancer

Koay Team Wins Texas Cancer Prevention Funding

Eugene Koay's research team was selected for Cancer Prevention and Research Institute of Texas (CPRIT) funding. The team studies how mechanical forces and metabolism in pancreatic cysts called IPMNs contribute to the development of cancer.

Why it matters

Pancreatic cancer is among the deadliest cancers, and IPMNs are cysts that can progress to it. The research may lead to a way to identify patients at highest risk before the disease becomes deadly.

The announcement is an institutional funding selection rather than a measured result, and no quantitative figures were reported. It is not yet known how much funding the team received or how long the study will run.

The players

Cancer Prevention and Research Institute of Texas (CPRIT)

CPRIT is a state agency created by voter-approved legislation to fund cancer research, prevention and treatment in Texas.

Eugene Koay

Koay is Professor and Scientific Director of the Ahmed Center for Pancreatic Cancer Research at MD Anderson Cancer Center.

MD Anderson Cancer Center

MD Anderson is a major cancer hospital and research institution in Houston, part of the University of Texas System.

The details

The research team, which includes investigators from MD Anderson Cancer Center and ARTIDIS, is examining mechanical forces and metabolism in IPMN cysts of the pancreas. Koay announced the selection on LinkedIn, and the work aims to show how these cysts contribute to cancer development.

Timeline

  1. November 20, 2026: Eugene Koay announced the CPRIT funding selection on LinkedIn.

Big Picture

This selection is one of the awards made through the Cancer Prevention and Research Institute of Texas, the state program that funds early-detection and prevention research in Texas. It extends CPRIT's emphasis on catching cancer risk before disease becomes advanced.

For Texans, this funding signals that state dollars are supporting research aimed at identifying high-risk pancreatic cysts earlier. Patients with IPMNs may eventually benefit from better tools to decide who needs closer monitoring.

The takeaway

Early detection matters most for hard-to-treat cancers. Patients diagnosed with pancreatic cysts should discuss monitoring plans with their physicians, since research on identifying high-risk IPMNs is still developing.

Further reading

Explore more Cancer coverage to see how researchers are working to detect and prevent the disease earlier.

Source note: This article includes information reported by Oncodaily - Oncology News, Insights, Stories.